# OnCo record nct05552222 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05552222/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05552222", "NCT05552222" ;
  schema:name "A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal"@en ;
  schema:alternateName "MajesTEC-7"@en ;
  schema:description "A phase 3 trial of Teclistamab, Daratumumab, Lenalidomide in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05552222/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05552222> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-10-25" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-transplant-ineligible/> ;
  onco:technologies <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/talquetamab/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .